MIGDAL HA'EMEQ, Israel, Aug. 22, 2013 (GLOBE NEWSWIRE) -- Enzymotec Ltd. ("Enzymotec") today announced that it has filed a registration statement on Form F-1 with the Securities and Exchange Commission for a proposed initial public offering of shares of its ordinary shares. The number of shares to be offered and the price range for the proposed offering have not yet been determined. Enzymotec has applied to list its ordinary shares on the Nasdaq Global Market under the ticker symbol "ENZY."
BofA Merrill Lynch and Jefferies LLC will act as joint book-running managers for the proposed offering. Wells Fargo Securities, LLC will act as lead manager for the proposed offering. Canaccord Genuity and Wedbush Securities will act as co-managers for the proposed offering.
The offering will be made only by means of a prospectus. When available, a copy of the preliminary prospectus relating to the offering may be obtained from either: BofA Merrill Lynch, 222 Broadway, New York, NY 10038, Attention: Prospectus Department or emailing email@example.com; or Jefferies LLC, 520 Madison Ave, 12th Floor, New York, NY 10022, 877-547-6340, email: Prospectus_Department@Jefferies.com.
A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy these securities be accepted prior to the time the registration statement becomes effective.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Enzymotec Ltd.
Enzymotec is a leading global supplier of specialty lipid-based products and solutions. The Company develops, manufactures and markets innovative bio-functional lipid ingredients, as well as final products, based on sophisticated processes and technologies.
CONTACT: ICR Katie Turner 646-277-1228 Katie.Turner@icrinc.comSource:Enzymotec Ltd.